SynthesisRespiratory research2006
Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.
Synthesis in Respiratory research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Long-acting beta2-agonists for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2013Pooled it
- [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].Atencion primaria · 2012Guideline
- Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation.Trials · 2012Trial
- Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy.Annals of translational medicine · 2020Review
- Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.Heart failure reviews · 2017Review
- Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2014Review
- The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.Expert review of clinical pharmacology · 2013Review
- [Alveolar epithelial cell injury as an etiopathogenic factor in pulmonary fibrosis].Archivos de bronconeumologia · 2012Review
- Epidemiology and management of common pulmonary diseases in older persons.The journals of gerontology. Series A, Biological sciences and medical sciences · 2012Review
- Determinants of spirometry use and accuracy of COPD diagnosis in primary care.Journal of general internal medicine · 2011Article
- Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.Respiratory research · 2010Review
- Chronic obstructive pulmonary disease in the elderly: an update on pharmacological management.Drugs & aging · 2009Review
- Targeted treatment in COPD: a multi-system approach for a multi-system disease.International journal of chronic obstructive pulmonary disease · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have demonstrated that long-acting beta2-agonists such as salmeterol are beneficial in chronic obstructive pulmonary disease (COPD). A meta-analysis was therefore conducted to review studies in COPD to provide pooled estimates of the effect of salmeterol 50 mcg taken twice daily in addition to usual therapy on several clinically relevant endpoints, when compared with placebo/usual therapy.
methodsAn extensive search of literature and clinical trial databases was conducted using the terms salmeterol, COPD, chronic, obstructive, bronchitis and emphysema. Nine randomized, double-blind, parallel-group, placebo-controlled trials of > or =12 week duration with salmeterol 50 mcg bid treatment in COPD were included (>3500 patients), with a further 14 trials excluded due to study design or reporting timelines. All patients were included, and a sub-group of subjects (84%) with poorly reversible COPD were considered separately. Statistical testing was carried out at the 5% level, except for interaction testing which was carried out at the 10% level.
resultsPatients treated with salmeterol over 12 months were less likely to withdraw early from the studies (19% patients compared with 25% on their current usual therapy, p < 0.001), less likely to suffer a moderate/severe exacerbation (34% compared with 39%, p < 0.0001) and had a greater increase in average FEV1 (73 mL difference vs placebo/usual therapy, p < 0.0001). Similar differences were found at 3 and 6 months. At all time points, more patients experienced an improvement in health status and also a greater change with salmeterol than with placebo/usual therapy (p < 0.002). There was no evidence of tachyphylaxis to salmeterol over 12 months.
conclusionThe meta-analysis confirmed clinically and statistically significant, sustained and consistent superiority of salmeterol 50 mcg bid over placebo/usual therapy on a broad range of outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.